Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Resisting antimicrobial resistance

To control antimicrobial resistance (AMR) will require approaches to develop, share and preserve antibiotics that are scaled to the scientific, economic and ethical dimensions of the crisis. The three cooperative, interdisciplinary, international councils proposed here exemplify what this will require.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Roope, L. S. J. et al. The challenge of antimicrobial resistance: what economics can contribute. Science 364, eaau4679 (2019).

    Article  CAS  Google Scholar 

  2. The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (2016).

  3. Nathan, C. & Cars, O. Antibiotic resistance — problems, progress, and prospects. N. Engl. J. Med. 371, 1761–1763 (2014).

    Article  Google Scholar 

  4. Laxminarayan, R., Sridhar, D., Blaser, M., Wang, M. & Woolhouse, M. Achieving global targets for antimicrobial resistance. Science 353, 874–875 (2016).

    Article  CAS  Google Scholar 

  5. Nathan, C. Aligning pharmaceutical innovation with medical need. Nat. Med. 13, 304–308 (2007).

    Article  CAS  Google Scholar 

  6. Nielsen, T. B., Brass, E. P., Gilbert, D. N., Bartlett, J. G. & Spellberg, B. Sustainable discovery and development of antibiotics - is a nonprofit approach the future? N. Engl. J. Med. 381, 503–505 (2019).

    Article  Google Scholar 

  7. Outterson, K. et al. Delinking investment in antibiotic research and development from sales revenues: the challenges of transforming a promising idea into reality. PLoS Med. 13, e1002043 (2016).

    Article  Google Scholar 

  8. Årdal, C. et al. Drive-AB Report. Revitalizing the antibiotic pipeline. http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Final-Report-Jan2018.pdf (2018).

  9. Barbier, E. Sustainability: tax ‘societal ills’ to save the planet. Nature 483, 30 (2012).

    Article  CAS  Google Scholar 

  10. Nathan, C. F. Cooperative development of antimicrobials: looking back to look ahead. Nat. Rev. Microbiol. 13, 651–657 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carl Nathan.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Related links

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X): https://carb-x.org

Global Antibiotic Research and Development Partnership (GARDP): https://www.gardp.org

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nathan, C. Resisting antimicrobial resistance. Nat Rev Microbiol 18, 259–260 (2020). https://doi.org/10.1038/s41579-020-0348-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41579-020-0348-5

This article is cited by

Search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology